Cresset, a provider of chemistry software and services, has chosen ProMining Therapeutics to license SparkV10 for assistance in its hit-to-lead optimisation efforts. SparkV10 is Cresset’s desktop bioisostere software tool, which is used by medicinal and computational chemists for drug design.
Dr David Bardsley, Cresset’s sales director, said: 'SparkV10 is an exciting and powerful way of generating novel and diverse structures. We are delighted that ProMining, an early-stage biopharmaceutical research and development company, has chosen to work with sparkV10 for the development of small molecule drugs.'
ProMining Therapeutics' CTO Dr Boaz Inbal, added: 'We are excited about using SparkV10 in our oncology project. We believe SparkV10 will guide us through several optimisation challenges.
'As a result, we will be able to better understand the behaviour of several chemical groups in the context of our hit scaffold and to test some required replacement hypotheses.'